Form 4: Lixte Biotechnology Director Receives Stock Options in Lieu of Cash Compensation
SEC Form 4 Filing
Lixte Biotechnology Holdings director, Rene Bernards, received stock options in lieu of cash compensation, according to a recent SEC filing.
Summary
- Rene Bernards, a director at Lixte Biotechnology Holdings, received 4,166 stock options on January 20, 2025.
- These options were granted in lieu of quarterly cash compensation under the Board Compensation Plan.
- The options have an exercise price of $2.33 and vest immediately.
- The options expire on January 20, 2030.
- Mr. Bernards also holds other options with different exercise prices and expiration dates.
Sentiment
Score: 7
Explanation: The document reflects a standard compensation practice, which is generally positive for aligning director and shareholder interests. There are no negative implications.
Positives
- The grant of stock options aligns the director's interests with those of the shareholders.
- The immediate vesting of the options provides an immediate incentive for the director.
Risks
- The exercise of these options could potentially dilute existing shareholders' ownership.
Management Comments
- The stock options were granted in lieu of quarterly cash compensation due to the reporting person under the Board Compensation Plan.
Industry Context
It is common practice for companies, especially in the biotech sector, to use stock options as part of director compensation packages to align interests and conserve cash.
Comparison to Industry Standards
- Stock option grants are a standard form of compensation for directors in publicly traded companies, particularly in the biotechnology sector.
- The vesting schedule of immediately vesting is less common than a phased vesting schedule, but is not unusual.
- The exercise price of $2.33 is specific to Lixte Biotechnology's stock price at the time of the grant.
Stakeholder Impact
- Shareholders may view this as a positive move as it aligns the director's interests with the company's performance.
- The grant of options may have a minor dilutive effect on existing shareholders.
Key Dates
| Date | Description |
|---|---|
| 06/30/2024 | Expiration date for some of the director's existing options. |
| 09/30/2024 | Expiration date for some of the director's existing options. |
| 01/20/2025 | Date of the stock option grant to Rene Bernards. |
| 01/20/2025 | Vesting date of the stock options granted to Rene Bernards. |
| 01/20/2030 | Expiration date of the stock options granted to Rene Bernards. |
| 01/22/2025 | Date of the SEC filing. |
Keywords
stock options, director compensation, insider trading, Lixte Biotechnology, equity, Rene Bernards
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.